Clear market notes built around the JSE, the rand, and what matters locally.

2026-07-15 22:19 • The Motley Fool Positive Axe Cap view: Selective

The article recommends three semiconductor stocks as attractive buys during the recent AI chip sector pullback: Nvidia, AMD, and Broadcom. Nvidia maintains dominance in AI model training through its CUDA platform and is expanding into inference and networking. AMD is positioned to benefit from inference workloads and agentic AI trends, which require more CPU participation. Broadcom is capitalizing on hyperscalers' adoption of custom AI accelerators, with significant growth expected from partnerships with major tech companies.

Axe note: A recent dip in AI chip stocks creates a buying opportunity, but South Africans should look through to USD/ZAR and cautious sector plays.

2026-07-15 22:10 • The Motley Fool Mixed Axe Cap view: Selective

IBM issued a profit warning for Q2, missing earnings expectations as customers shifted spending toward memory, servers, and storage amid tight supply and anticipated price increases. This reflects a temporary shift in AI market dynamics where different players benefit at different times. While memory companies like Micron and SK Hynix are currently winning, the article suggests investors should maintain diversified AI portfolios rather than chasing trends, as broader tech companies like IBM and Microsoft may benefit long-term from integrated AI capabilities.

Axe note: IBM's earnings miss highlights a short-term move toward memory and storage in AI spending, shaping which tech companies currently benefit.

2026-07-15 22:09 • The Motley Fool Neutral Axe Cap view: Selective

Precigen CFO Harry Thomasian Jr. sold 200,000 shares worth $1.1 million in early July 2026, reducing his direct holdings by 36%. However, the sale was part of a pre-arranged Rule 10b5-1 trading plan and should not be viewed as a red flag. The biotech company has shown strong momentum with Q1 revenue of $23.3 million and FDA orphan drug status for its Papzimeos treatment.

Axe note: Precigen’s CFO sold a sizable chunk of shares, but context matters more than the headline.